A grant to fund the First in Human, Phase 1a clinical study of anti-METH ch-mAb7F9 was awarded to UAMS and InterveXion. This three year, $3 million, award will be used to test the safety of the chimeric antibody in healthy human volunteers.
NIDA Funds the First Clinical Trial of an Anti-Methamphetamine Antibody
Jul 15, 2011 | Anti-METH ch-mAb7F9, Grants, Uncategorized
Recent Comments